A carregar...
A phase II trial of dasatinib in advanced melanoma
RATIONALE: Inhibiting Src kinases (non-receptor tyrosine kinase signaling intermediates) reduces melanoma cell proliferation and invasion. Dasatinib inhibits c-kit, PDGFβR and EPHA2 and src kinases c-Src, c-Yes, Lck and Fyn. We conducted a phase 2 trial of dasatinib in melanoma to assess response ra...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3116034/ https://ncbi.nlm.nih.gov/pubmed/21523734 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25766 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|